Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

positioned to win future contracts in the vaccine and oncology fields. As a result, the Company believes stockholder value will be maximized by moving ahead independently, while continuing to focus on clinical vaccine development.

Dr. Kai Lindevall, executive chairman stated, "We are very pleased that we were able to close this financing to shore up our balance sheet and provide the Company with additional working capital. Our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long term potential we have to grow into a leading vaccine franchise with expertise in pre-clinical support, regulatory consultancy and strategic trial planning. We believe these developments will position us to move ahead independently and are in the best interest of all stockholders."

Of the 35,000,000 authorized capital stock of the Company, 26,325,383 shares of common stock will be issued and outstanding immediately following the closing.

The shares of common stock issued in connection with the above transactions have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under the Securities Act and applicable state securities laws or an applicable exemption from those registration requirements. The Exchange Shares will be immediately freely transferable pursuant to Rule 144 of the Act since the Investors are not affiliates of the Company and since the Investors will be deemed to have held the Exchange Shares for greater than 6 months pursuant to (d)(3)(ii) of Rule 144. For additional information on the transactions described below, please see our Current Report on Form 8-K filed with the SEC on October 19, 2009, which is available on the SEC website at www.sec.gov

Quarterly Results and Conference Call

Financial results for the third q
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
(Date:8/26/2015)... BEIJING , August 26, 2015 Israel ... DiaCardio wins 1 st place  Wayerz comes ... in Israel by venture capital fund JVP, ... including the US, China , Israel ... America .  Impressive achievement for the Israeli representatives ...
(Date:8/26/2015)... 26, 2015 After litigating and negotiating ... relating to P2i United States patent ... in the United States without any ... of either party. As a result of the parties, settlement, ... California dismissed the case without prejudice. ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial ... with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to ... regulatory pathways., , Stem Cell Meeting on the Mesa ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... In an address to,shareholders at the company,s ... ) Chairman and CEO David B. Snow Jr. ... designed to deliver strong,continuing earnings growth through 2008 ... specialty pharmacy to retaining and winning,customers, and advanced ...
... May 22 /PRNewswire-FirstCall/ - In accordance with the,terms ... Inc.,"Atrium" (TSX: ATB) today announced that it has ... Chemicals division for total proceeds of,US$166.4 million in ... is now a health and nutrition pure-play and ...
... CT Injection System Technology Detects Extravasations during CT ... ... MEDRAD, INC., announced today,that its XDS(TM) Extravasation Detector has ... a technology that aids in the,detection of leaking intravenous contrast ...
Cached Biology Technology:Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 2Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 3Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 4MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 2MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 3
(Date:8/24/2015)... 2015 The consulting company Frost & ... manufacturer DERMALOG and its customized solutions and products for ... of the Year Award". DERMALOG is particularly successful with a ... -Cross reference: Picture is available at AP Images ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... fond of talking about it as are politicians, economists ... The problem is that the term sustainability can refer ... at the Technische Universitaet Muenchen have shed light on ... science they have managed to give the term "sustainability" ...
... School of Medicine found that women may have a slightly higher ... acute coronary syndrome (ACS), but that these differences appear to be ... study, published in the August 26, 2009 issue of the ... however that overall there was no significant difference in mortality observed ...
... use wireless sensors, which can monitor chemical processes or ... wireless network. Still, many facilities that could benefit ... use a wired network instead, because the reliability, speed ... do not meet their needs. The U.S. ...
Cached Biology News:New tools for sustainable farming 2New tools for sustainable farming 3Study finds women slightly more likely to die than men in the 30 days following a heart attack 2SRNL, automakers to develop high-performance wireless sensors networks 2SRNL, automakers to develop high-performance wireless sensors networks 3
...
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
... degradation of single-stranded DNA and RNA endonucleolytically ... nuclease prefers ssDNA over dsDNA by 30,000-fold, ... double-stranded DNA from both ends (1,2). Mung ... mapping studies (3,4), for flushing staggered ends ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: